杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/11/10 | 1,738 | 1,743 | 1,712 | 1,742 | -44 | -2.5% | 189,600 |
| 2022/11/09 | 1,789 | 1,793 | 1,777 | 1,786 | ±0 | ±0% | 39,200 |
| 2022/11/08 | 1,773 | 1,794 | 1,768 | 1,786 | +16 | +0.9% | 50,500 |
| 2022/11/07 | 1,771 | 1,782 | 1,760 | 1,770 | +4 | +0.2% | 53,000 |
| 2022/11/04 | 1,790 | 1,790 | 1,758 | 1,766 | -49 | -2.7% | 92,300 |
| 2022/11/02 | 1,811 | 1,824 | 1,798 | 1,815 | +6 | +0.3% | 106,400 |
| 2022/11/01 | 1,840 | 1,845 | 1,805 | 1,809 | -30 | -1.6% | 32,100 |
| 2022/10/31 | 1,811 | 1,844 | 1,811 | 1,839 | +36 | +2% | 65,200 |
| 2022/10/28 | 1,790 | 1,817 | 1,784 | 1,803 | +4 | +0.2% | 314,300 |
| 2022/10/27 | 1,803 | 1,813 | 1,787 | 1,799 | -5 | -0.3% | 51,300 |
| 2022/10/26 | 1,783 | 1,811 | 1,781 | 1,804 | +31 | +1.7% | 54,300 |
| 2022/10/25 | 1,776 | 1,782 | 1,764 | 1,773 | +8 | +0.5% | 85,200 |
| 2022/10/24 | 1,781 | 1,783 | 1,761 | 1,765 | -14 | -0.8% | 74,600 |
| 2022/10/21 | 1,780 | 1,787 | 1,774 | 1,779 | -9 | -0.5% | 39,300 |
| 2022/10/20 | 1,800 | 1,806 | 1,783 | 1,788 | -26 | -1.4% | 62,800 |
| 2022/10/19 | 1,816 | 1,825 | 1,808 | 1,814 | -2 | -0.1% | 51,000 |
| 2022/10/18 | 1,830 | 1,834 | 1,810 | 1,816 | +9 | +0.5% | 73,000 |
| 2022/10/17 | 1,810 | 1,822 | 1,800 | 1,807 | -15 | -0.8% | 43,700 |
| 2022/10/14 | 1,834 | 1,834 | 1,816 | 1,822 | +19 | +1.1% | 91,600 |
| 2022/10/13 | 1,811 | 1,812 | 1,799 | 1,803 | -7 | -0.4% | 59,100 |
| 2022/10/12 | 1,805 | 1,825 | 1,803 | 1,810 | +10 | +0.6% | 55,900 |
| 2022/10/11 | 1,825 | 1,825 | 1,793 | 1,800 | -26 | -1.4% | 64,700 |
| 2022/10/07 | 1,810 | 1,830 | 1,796 | 1,826 | -1 | -0.1% | 56,900 |
| 2022/10/06 | 1,820 | 1,834 | 1,816 | 1,827 | +19 | +1.1% | 78,600 |
| 2022/10/05 | 1,803 | 1,814 | 1,800 | 1,808 | +5 | +0.3% | 80,100 |
| 2022/10/04 | 1,779 | 1,805 | 1,779 | 1,803 | +34 | +1.9% | 91,500 |
| 2022/10/03 | 1,768 | 1,773 | 1,752 | 1,769 | -1 | -0.1% | 54,200 |
| 2022/09/30 | 1,788 | 1,797 | 1,766 | 1,770 | -15 | -0.8% | 100,100 |
| 2022/09/29 | 1,767 | 1,793 | 1,748 | 1,785 | +33 | +1.9% | 93,800 |
| 2022/09/28 | 1,720 | 1,757 | 1,712 | 1,752 | +24 | +1.4% | 82,100 |
| 2022/09/27 | 1,721 | 1,737 | 1,720 | 1,728 | +4 | +0.2% | 85,900 |
| 2022/09/26 | 1,733 | 1,742 | 1,715 | 1,724 | -21 | -1.2% | 97,900 |
| 2022/09/22 | 1,771 | 1,771 | 1,741 | 1,745 | -21 | -1.2% | 77,000 |
| 2022/09/21 | 1,744 | 1,769 | 1,744 | 1,766 | +7 | +0.4% | 72,100 |
| 2022/09/20 | 1,749 | 1,760 | 1,740 | 1,759 | +16 | +0.9% | 75,300 |
| 2022/09/16 | 1,735 | 1,748 | 1,735 | 1,743 | -2 | -0.1% | 38,200 |
| 2022/09/15 | 1,746 | 1,747 | 1,738 | 1,745 | ±0 | ±0% | 47,700 |
| 2022/09/14 | 1,760 | 1,764 | 1,743 | 1,745 | -45 | -2.5% | 61,100 |
| 2022/09/13 | 1,778 | 1,795 | 1,778 | 1,790 | +13 | +0.7% | 51,400 |
| 2022/09/12 | 1,783 | 1,786 | 1,763 | 1,777 | -6 | -0.3% | 98,400 |
| 2022/09/09 | 1,794 | 1,803 | 1,783 | 1,783 | -11 | -0.6% | 83,300 |
| 2022/09/08 | 1,773 | 1,794 | 1,770 | 1,794 | +38 | +2.2% | 111,900 |
| 2022/09/07 | 1,759 | 1,771 | 1,741 | 1,756 | -7 | -0.4% | 59,400 |
| 2022/09/06 | 1,764 | 1,772 | 1,752 | 1,763 | +9 | +0.5% | 125,400 |
| 2022/09/05 | 1,752 | 1,767 | 1,744 | 1,754 | -9 | -0.5% | 39,200 |
| 2022/09/02 | 1,768 | 1,768 | 1,746 | 1,763 | +10 | +0.6% | 53,500 |
| 2022/09/01 | 1,740 | 1,768 | 1,740 | 1,753 | +1 | +0.1% | 82,700 |
| 2022/08/31 | 1,745 | 1,770 | 1,744 | 1,752 | -14 | -0.8% | 84,900 |
| 2022/08/30 | 1,754 | 1,770 | 1,752 | 1,766 | +8 | +0.5% | 41,300 |
| 2022/08/29 | 1,745 | 1,767 | 1,745 | 1,758 | -11 | -0.6% | 59,100 |
501～
550
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.27倍 | 1.47倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
